Abstracts tagged "Antiphospholipid antibodies"

Abstract Number: 556 • 2013 ACR/ARHP Annual Meeting
Depletion Of The Gut Microbiota Prevents β₂-Glycoprotein I Antibody Production and Mortality In a Model Of Antiphospholipid Syndrome
Silvio M. Vieira¹, Andrew Yu¹, Odelya E. Pagovich¹, Eleni Tiniakou², John Sterpka¹ and Martin A. Kriegel^3,4, ¹Yale School of Medicine, New Haven, CT, ²Yale University School of Medicine, New Haven, CT, ³Immunobiology, Yale School of Medicine, New Haven, CT, ⁴Medicine/Division of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: Infectious triggers have been implicated in transient antiphospholipid antibody production in both mice and humans. The cause of persistent anti-β2-glycoprotein I (β2GPI) antibody production…
Abstract Number: 19 • 2013 ACR/ARHP Annual Meeting
Association Of Antiphospholipid Antibodied Detected In The Aphl ELISA With Clinical Manifestations Of The Antiphospholipid Syndrome In Two Lupus Cohorts
Silvia S. Pierangeli¹, Rohan Willis², Michelle Petri³, Hong Fang⁴, Monica Smikle⁵, Karel de Ceulaer⁶ and E. Nigel Harris⁷, ¹Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ²Int Medicine/Rheumatology, University of Texas Medical Branch, Galveston, TX, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Microbiology, University of the West Indies, Kgn 7, Jamaica, ⁶Microbiology, University of the West Indies, KIngston, Jamaica, ⁷Office of the Vice Chancellor, The University of the West Ind, Kingston, Jamaica
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by the presence of antibodies to phospholipid (aPL) and to β2glycoprotein I (β2GPI) in patients with thrombosis or pregnancy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].